Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go:
Stretch
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
Studio Pictures Ltd is a UK-based film and TV production company founded by producers Adam Rolston and David Braithwaite in 2019. Specializing in creating high-quality British entertainment content, the company focuses on adapting books to screen and telling unique true-life stories that entertain and inspire both domestic and international audiences. With successful productions like "A Street Cat Named Bob," the company is building a strong brand and reputation in the industry. Studio Pictures has access to top creative talent and collaborates with major studios like Warner Bros, Sony Pictures, Lionsgate, and Studio Canal. The company is located at Twickenham Studios in Richmond, UK.
days to go:
11
investment:
Withheld
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Qynn is an investment opportunity and the world’s foremost provider of corporate information and insight on the unlisted UK SME market. The company has four live products: Hunter, QBase, Playground, and Qynn Score. In the next six months, the company will release many new products to multiply the current data stack. Qynn aims at creating the world's most advanced company search tool. With the proceeds, the company will be able to drive sales and product development.
days to go:
Expired
investment:
£310,009
Opportunity Network is a digital network that provides equal growth opportunities to Chief Executive Officers (CEO). The portal's algorithm vets prospective users, allows them to buy, sell, raise or invest in an asset, gives them the option to choose the industry they wish to do business in, and then post their requirement for the same. The user can then select the best deal for their business from a list of responses and scale profitably. The company's platform connects 32,000+ qualified CEOs in 130+ countries to $295 billion worth of commercial, financial, and mergers and acquisitions (M&A) deals. 86% of the deals on the portal find at least 1 counterpart in 48 hours. Opportunity Network aims to reach full scale by the end of 2020 and find 10 counterparts for 95% of the deals in 1 hour. The company has also been featured in publications such as Forbes, CNBC, Financial Times, and The Economist. It will use the investment to scale its business across various verticals.
days to go:
Expired
investment:
£962,500
Run3D is a biotechnology company that has developed a 3D gait analysis system with the aim to help people identify injuries, deliver better performance, and make better running decisions. 3D gait analysis involves using infrared cameras to track positions of small reflective markers attached to a person in motion, capturing measurable data to help quantify a person's risk of injury, biomechanical efficiency, performance, footwear, and recommend proper diagnosis where necessary. The company plans to use the investment to grow its business.
days to go:
Expired
investment:
Withheld
Chip is a wealth investing & savings app that aims to foster financial prosperity for today's generation
days to go:
Expired
investment:
£5,083,686
Lifetise generates proprietary consumer data via its portal to boost the Artificial Intelligence (AI) based decision-making process within banks and insurers and increase their product sales. Lifetise asserts that its portal helps financial institutions acquire and fulfil the needs of high-value customers at a lower cost to the organisation. It is in negotiations with three retail banks and is an Accenture Fintech Lab alumni. The company was named as one of the most influential financial technology entities of 2020 by The Financial Technologist magazine and selected for the Mayor of London's 'Business Growth Programme' under the 'Most high potential startups' category in 2021. Lifetise will use 58% of the investment in product development and engineering to scale its technology platform, 31% on sales and marketing, and 11% on operations.
days to go:
Expired
investment:
£369,407
